• Molecular NameMemantine
  • SynonymDMAA; Memantina [INN-Spanish]; memantine; Memantine [INN]; Memantine HCL; Memantine Hydrochloride; Memantinum [INN-Latin]
  • Weight179.307
  • Drugbank_IDDB01043
  • ACS_NO19982-08-2
  • Show 3D model
  • LogP (experiment)3.28
  • LogP (predicted, AB/LogP v2.0)3.45
  • pka10.27
  • LogD (pH=7, predicted)0.5
  • Solubility (experiment)35 mg/ml (HCl salt), 0.9 mg/ml for free base
  • LogS (predicted, ACD/Labs)(ph=7)0.23
  • LogSw (predicted, AB/LogsW2.0)0.18
  • Sw (mg/ml) (predicted, ACD/Labs)0.47
  • No.of HBond Donors2
  • No.of HBond Acceptors1
  • No.of Rotatable Bonds0
  • TPSA26.02
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyThe first in a novel class of Alzheimer's disease medications acting on the glutamatergic system by blocking NMDA glutamate receptors.
  • Absorption_value100.0
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability100.0
  • Protein binding45.0
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmHepatic (<10%)
  • Half life60~100 h
  • ExcretionRenal
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicitySide effects include pain, abnormal crying, leg pain, fever, increased apetite. Adverse drug reactions include: dizziness, confusion, headache, hallucinations, tiredness. Less common side effects include: vomiting, anxiety, hypertonia, cystitis, and increased libido. Doses of up to 400 mg have been tolerated.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A